Fujifilm (OTCMKTS:FUJIY) Share Price Crosses Above 200-Day Moving Average - Time to Sell?

Key Points

• Fujifilm shares crossed above their 200-day moving average of $10.65, reaching a high of $12.39 during trading.
• Analysts at Wall Street Zen have downgraded Fujifilm from a "buy" rating to a "hold" rating as of May 23rd.
• The company's latest earnings report revealed an EPS of $0.15, meeting analysts' expectations, amidst a revenue of $5.08 billion for the quarter.

Fujifilm Holdings Corp. (OTCMKTS:FUJIY - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $10.65 and traded as high as $12.39. Fujifilm shares last traded at $12.36, with a volume of 58,957 shares changing hands.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered shares of Fujifilm from a "buy" rating to a "hold" rating in a research report on Friday, May 23rd.

Fujifilm Stock Performance

The company has a market cap of $30.75 billion, a price-to-earnings ratio of 11.14, a P/E/G ratio of 2.33 and a beta of 0.67. The company has a current ratio of 1.48, a quick ratio of 0.92 and a debt-to-equity ratio of 0.17. The stock's 50 day moving average price is $11.21 and its 200 day moving average price is $10.65.

Fujifilm (OTCMKTS:FUJIY - Get Free Report) last released its earnings results on Wednesday, August 6th. The technology company reported $0.15 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.15. Fujifilm had a net margin of 7.93% and a return on equity of 7.60%. The firm had revenue of $5.08 billion during the quarter, compared to the consensus estimate of $760.41 billion. On average, analysts expect that Fujifilm Holdings Corp. will post 0.66 EPS for the current fiscal year.

Fujifilm Company Profile

FUJIFILM Holdings Corporation develops, manufactures, sells, and services imaging, healthcare, materials, and business innovation solutions worldwide. The company's Healthcare segment provides products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.